Insider Buying: Indivior (NASDAQ:INDV) Director Acquires 775 Shares of Stock

January 8, 2026 by InsiderTrades.com

Key Points

Director David E. Wheadon bought 1,771 shares at $35.39 (≈$62,675), increasing his stake to 14,395 shares (+14.03%); combined with purchases by other directors (roughly 4,871 shares), these insider purchases signal board‑level confidence.
Indivior issued full‑year 2026 guidance calling for $1,125M–$1,195M in total net revenue, SUBLOCADE net revenue of $905M–$945M and adjusted EBITDA of $535M–$575M, implying a mid‑40% margin and that SUBLOCADE remains the primary revenue driver.
The company recently beat quarterly estimates (EPS $0.72 vs $0.38 est.; revenue $314M vs $257.7M) and maintains a Wall Street consensus rating of Buy with an average price target of $32.71.

Indivior PLC (NASDAQ:INDV - Get Free Report) Director Mark Stejbach purchased 775 shares of Indivior stock in a transaction dated Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director owned 16,847 shares in the company, valued at approximately $596,215.33. This trade represents a 4.82% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Indivior Trading Down 0.8%

Shares of INDV opened at $35.89 on Thursday. Indivior PLC has a 12-month low of $7.62 and a 12-month high of $38.00. The firm has a 50-day moving average price of $33.91 and a 200 day moving average price of $25.66. The firm has a market capitalization of $4.49 billion, a P/E ratio of 39.01 and a beta of 0.75.

Indivior (NASDAQ:INDV - Get Free Report) last issued its earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. Equities research analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Key Stories Impacting Indivior

Here are the key news stories impacting Indivior this week:

Positive Sentiment: Indivior issued full‑year 2026 guidance calling for total net revenue of $1,125M–$1,195M, SUBLOCADE net revenue of $905M–$945M, non‑GAAP operating expenses of $430M–$450M, and adjusted EBITDA of $535M–$575M. The guidance implies SUBLOCADE will remain the company’s primary revenue driver and an implied adjusted EBITDA margin in the mid‑40% range, which investors view as strong profitability guidance for 2026. Indivior Provides Full-Year 2026 Financial Guidance and Business Update
Positive Sentiment: Director David E. Wheadon purchased 1,771 shares at an average price of $35.39, increasing his stake by ~14% — a sign of insider confidence. Form 4 — David E. Wheadon
Positive Sentiment: Directors Mark Stejbach, Daniel A. Ninivaggi, Keith Humphreys and Barbara Ryan each bought 775 shares at ~$35.39, modestly increasing their holdings; combined insider purchases across these filings total roughly 4,871 shares, signaling broad board-level conviction. Form 4 — Mark Stejbach Form 4 — Daniel A. Ninivaggi Form 4 — Keith Humphreys Form 4 — Barbara Ryan

Wall Street Analysts Forecast Growth

Several research firms have issued reports on INDV. Piper Sandler reissued an "overweight" rating and set a $41.00 target price (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Northland Securities set a $40.00 price target on Indivior in a report on Friday, October 31st. HC Wainwright raised their price objective on Indivior from $28.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. Zacks Research raised shares of Indivior from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Indivior in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Indivior presently has an average rating of "Buy" and a consensus target price of $32.71.

View Our Latest Stock Report on INDV

Institutional Investors Weigh In On Indivior

Several institutional investors and hedge funds have recently modified their holdings of INDV. CWM LLC acquired a new position in Indivior during the 3rd quarter worth about $25,000. Quarry LP purchased a new stake in Indivior during the third quarter worth about $26,000. GAMMA Investing LLC lifted its position in shares of Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company's stock worth $43,000 after purchasing an additional 1,013 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Indivior during the second quarter worth about $26,000. Finally, Plato Investment Management Ltd purchased a new position in shares of Indivior in the third quarter valued at approximately $52,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Company Profile

(Get Free Report)

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company's portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.